Is Corvus Pharmaceuticals, Inc. (CRVS) a Buy, Sell, or Hold?
NASDAQ : CRVS
Corvus Pharmaceuticals, Inc.
$14.27 USD
-$0.65 (-4.36%)
- Volume
- 1.24M
- Average Volume
- 1.6M
- Market Capitalization
- $1.2B
- P/E Ratio
- -25.95
- Dividend Yield
- 0.00%
- Price Target
- $31.00
- Year High
- $26.95
- Year Low
- $3.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $19.81
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Richard A. Miller |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CRVS |
| CUSIP | 221015100 |
| CIK | 0001626971 |
| Web | https://www.corvuspharma.com |
| Phone | 650 900 4520 |
| Currency | USD |
| Employees | 37 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 19.81 |
| Quick Ratio | 19.81 |
| Cash Ratio | 3.31 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -0.39 |
| Price / Cash Flow | -34.15 |
| Price / Book | 5.34 |
Price Target and Rating
| Average Stock Price Forecast | $31.00 |
| High Stock Price Forecast | $42.00 |
| Low Stock Price Forecast | $27.00 |
| Forecast Upside/Downside | -53.97% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.53 |
| Trailing P/E Ratio | -25.95 |
| PEG Ratio | 0.11 |
| P/E Growth | 0.11 |
| Net Income | -$15.28M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -38.92% |
| Return on Assets | -17.44% |
Financials Score
| AltmanZ Score | 58.32 |
| Piotroski Score | 2.00 |
| Working Capital | 227.84M |
| Total Assets | 253.2M |
| Ebit | -42.38M |
| Market Cap | 1.25B |
| Total Liabilities | 12.52M |
Poll Results
About Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed w ... ith either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
2026-06-23 15:20:04
David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026. This transaction marks Moore's first investment in the business.
2026-06-09 07:30:00
SOUTH SAN FRANCISCO, Calif. , June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13. 5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company's collaboration partner in China.
2026-06-09 07:30:00
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States $13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States
2026-06-08 13:58:32
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-05-20 16:01:00
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET.
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early
2026-05-19 13:34:11
Corvus Pharmaceuticals, Inc. remains a Sell as its valuation has run ahead of fundamentals following encouraging but limited Phase 1 AD data. Soquelitinib shows activity in atopic dermatitis, but questions remain on safety, durability, and efficacy in broader populations versus established treatments. My DCF analysis yields a fair value of $10.07/share, implying 16% downside from current levels, with significant future cash needs likely requiring dilution.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
2026-05-17 16:26:06
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
2026-05-14 18:50:45
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
Frequently Asked Questions
-
What is the current Corvus Pharmaceuticals, Inc. (CRVS) stock price?
-
Corvus Pharmaceuticals, Inc.(NASDAQ:CRVS) stock price is $14.27 in the last trading session. During the trading session, CRVS stock reached the peak price of $26.95 while $3.96 was the lowest point it dropped to. The percentage change in CRVS stock occurred in the recent session was --4.36% while the dollar amount for the price change in CRVS stock was -$0.65.
-
CRVS's industry and sector of operation?
-
The NASDAQ listed CRVS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRVS?
-
Richard A. Miller | Co-Founder, President, Chief Executive Officer & Chairman of the Board
Leiv Lea | Chief Financial Officer
William Benton Jones | Senior Vice President of Pharmaceutical Development
Peter A. Thompson FACP | Co-Founder & Independent Director
Jeffrey S. Arcara | Senior Vice President & Chief Business Officer -
How many employees does CRVS have?
-
Number of CRVS employees currently stands at 37. CRVS operates from 863 Mitten Road, South San Francisco, CA 94010, US.
-
Link for CRVS official website?
-
Official Website of CRVS is: https://www.corvuspharma.com
-
How do I contact CRVS?
-
CRVS could be contacted at phone #650 900 4520 and can also be accessed through its website. CRVS operates from 863 Mitten Road, South San Francisco, CA 94010, US.
-
How many shares of CRVS are traded daily?
-
The average number of CRVS shares traded daily for last 3 months was 1.6M.
-
What is the market cap of CRVS currently?
-
The market value of CRVS currently stands at $1.2B with its latest stock price at $14.27